Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling